| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 769 | 2017 |
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) C Pinto, F Di Fabio, S Siena, S Cascinu, FLR Llimpe, C Ceccarelli, V Mutri, ... Annals of Oncology 18 (3), 510-517, 2007 | 411 | 2007 |
| Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) C Pinto, F Di Fabio, C Barone, S Siena, A Falcone, S Cascinu, ... British journal of cancer 101 (8), 1261-1268, 2009 | 213 | 2009 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 131 | 2019 |
| Malignant peritoneal mesothelioma: a multicenter study on 81 cases V de Pangher Manzini, L Recchia, M Cafferata, C Porta, S Siena, ... Annals of oncology 21 (2), 348-353, 2010 | 130 | 2010 |
| Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ... British journal of cancer 113 (12), 1730-1734, 2015 | 80 | 2015 |
| Treatment of metastatic neuroendocrine carcinomas based on WHO classification S Artale, L Giannetta, G Cerea, D Maggioni, P Pedrazzoli, I Schiavetto, ... Anticancer research 25 (6C), 4463-4469, 2005 | 45 | 2005 |
| Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer F Cappuzzo, A Morabito, N Normanno, P Bidoli, A Del Conte, L Giannetta, ... Lung Cancer 99, 31-37, 2016 | 35 | 2016 |
| Optimising management of neutropenia and anaemia in cancer chemotherapy—advances in cytokine therapy S Siena, S Secondino, L Giannetta, O Carminati, P Pedrazzoli Critical reviews in oncology/hematology 48, S39-S47, 2003 | 27 | 2003 |
| Controversies in the management of brain metastases: the role of chemotherapy. G Landonio, A Sartore-Bianchi, L Giannetta, M Renga, M Riva, S Siena Forum (Genoa, Italy) 11 (1), 59-74, 2001 | 27 | 2001 |
| Efficacy and safety of anti-PD-1 immunotherapy in patients aged≥ 75 years with non–small-cell lung cancer (NSCLC): an Italian, multicenter, retrospective study A Luciani, A Marra, L Toschi, D Cortinovis, S Fava, V Filipazzi, A Tuzi, ... Clinical Lung Cancer 21 (6), e567-e571, 2020 | 26 | 2020 |
| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of … A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ... Targeted Oncology 12, 525-533, 2017 | 16 | 2017 |
| Liquid biopsy for small cell lung cancer either de novo or transformed: systematic review of different applications and meta-analysis EG Pizzutilo, M Pedrani, A Amatu, L Ruggieri, C Lauricella, SM Veronese, ... Cancers 13 (9), 2265, 2021 | 15 | 2021 |
| Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly G Cartenì, L Giannetta, G Ucci, G De Signoribus, A Vecchione, G Pinotti, ... Supportive Care in Cancer 15, 1057-1066, 2007 | 14 | 2007 |
| Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated … M Moroni, L Giannetta, G Gelosa, S Secondino, G Chillura, E Colombo, ... Journal of chemotherapy 15 (4), 394-399, 2003 | 13 | 2003 |
| Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma G Metro, D Signorelli, EG Pizzutilo, L Giannetta, G Cerea, M Garaffa, ... Human Vaccines & Immunotherapeutics 17 (9), 2972-2980, 2021 | 12 | 2021 |
| Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib R Esposito Abate, R Pasquale, A Sacco, MC Piccirillo, A Morabito, ... Cancers 11 (10), 1431, 2019 | 10 | 2019 |
| Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in … M Brose, B Jarzab, R Elisei, L Giannetta, L Bastholt, C Fouchardiere, ... Annals of Oncology 27, vi329, 2016 | 7 | 2016 |
| Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer A Sartore-Bianchi, G Cerea, I Schiavetto, L Giannetta, R Ricotta, ... Annals of oncology 17, ii49-ii51, 2006 | 7 | 2006 |
| Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or … M Schlumberger, R Elisei, F Pacini, B Jarzab, L Giannetta, L Bastholt, ... Thyroid 24, A6-7, 2014 | 6 | 2014 |
Salvatore SienaUniversità degli Studi di Milano, Dipartimento di Oncologia, Ospedale Niguarda, Milano, ItalyEmail verificata su unimi.it
